These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 21083927)

  • 1. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.
    French B; Joo J; Geller NL; Kimmel SE; Rosenberg Y; Anderson JL; Gage BF; Johnson JA; Ellenberg JH;
    Trials; 2010 Nov; 11():108. PubMed ID: 21083927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.
    Joo J; Geller NL; French B; Kimmel SE; Rosenberg Y; Ellenberg JH
    Clin Trials; 2010 Oct; 7(5):597-604. PubMed ID: 20693186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.
    Kimmel SE; French B; Anderson JL; Gage BF; Johnson JA; Rosenberg YD; Geller NL; Kasner SE; Eby CS; Joo J; Caldwell MD; Goldhaber SZ; Hart RG; Cifelli D; Madigan R; Brensinger CM; Goldberg S; Califf RM; Ellenberg JH
    Am Heart J; 2013 Sep; 166(3):435-41. PubMed ID: 24016491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic analysis and comparison of warfarin initiation strategies.
    French B; Wang L; Gage BF; Horenstein RB; Limdi NA; Kimmel SE
    Pharmacogenet Genomics; 2016 Oct; 26(10):445-52. PubMed ID: 27383664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.
    Gage BF; Bass AR; Lin H; Woller SC; Stevens SM; Al-Hammadi N; Li J; Rodríguez T; Miller JP; McMillin GA; Pendleton RC; Jaffer AK; King CR; Whipple BD; Porche-Sorbet R; Napoli L; Merritt K; Thompson AM; Hyun G; Anderson JL; Hollomon W; Barrack RL; Nunley RM; Moskowitz G; Dávila-Román V; Eby CS
    JAMA; 2017 Sep; 318(12):1115-1124. PubMed ID: 28973620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.
    Anderson JL; Horne BD; Stevens SM; Grove AS; Barton S; Nicholas ZP; Kahn SF; May HT; Samuelson KM; Muhlestein JB; Carlquist JF;
    Circulation; 2007 Nov; 116(22):2563-70. PubMed ID: 17989110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin pharmacogenetics.
    Limdi NA; Veenstra DL
    Pharmacotherapy; 2008 Sep; 28(9):1084-97. PubMed ID: 18752379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.
    Gong IY; Tirona RG; Schwarz UI; Crown N; Dresser GK; Larue S; Langlois N; Lazo-Langner A; Zou G; Roden DM; Stein CM; Rodger M; Carrier M; Forgie M; Wells PS; Kim RB
    Blood; 2011 Sep; 118(11):3163-71. PubMed ID: 21725053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Warfarin pharmacogenomics: current best evidence.
    Kimmel SE
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S266-71. PubMed ID: 26149035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized Anticoagulation: Optimizing Warfarin Management Using Genetics and Simulated Clinical Trials.
    Ravvaz K; Weissert JA; Ruff CT; Chi CL; Tonellato PJ
    Circ Cardiovasc Genet; 2017 Dec; 10(6):. PubMed ID: 29237680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.
    Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z
    J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Warfarin Dosing According to the Genotype-guided Algorithm is Most Beneficial in Patients With Atrial Fibrillation: A Randomized Parallel Group Trial.
    Makar-Aušperger K; Krželj K; Lovrić Benčić M; Radačić Aumiler M; Erdeljić Turk V; Božina N
    Ther Drug Monit; 2018 Jun; 40(3):362-368. PubMed ID: 29494423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
    Scott SA; Edelmann L; Kornreich R; Desnick RJ
    Am J Hum Genet; 2008 Feb; 82(2):495-500. PubMed ID: 18252229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.
    Hillman MA; Wilke RA; Yale SH; Vidaillet HJ; Caldwell MD; Glurich I; Berg RL; Schmelzer J; Burmester JK
    Clin Med Res; 2005 Aug; 3(3):137-45. PubMed ID: 16160068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype-guided dosing of warfarin through modeling and simulation.
    Deng J; Vozmediano V; Rodriguez M; Cavallari LH; Schmidt S
    Eur J Pharm Sci; 2017 Nov; 109S():S9-S14. PubMed ID: 28502675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
    Schalekamp T; Brassé BP; Roijers JF; Chahid Y; van Geest-Daalderop JH; de Vries-Goldschmeding H; van Wijk EM; Egberts AC; de Boer A
    Clin Pharmacol Ther; 2006 Jul; 80(1):13-22. PubMed ID: 16815313
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.